| Outcome Measures: |
Primary: fasting plasma glucose levels, Glucose levels will be measured after an overnight fast expressed in mmol/l., at week 12 of each intervention period | Secondary: whole-body insulin sensitivity, glucose clearance in ml/kg determined during an OGTT at 6 weeks glucose disposal rate (delta Rd) in umol/kg/min measured with the clamp at 12 weeks, at week 6 and week 12 of each intervention period|muscle mitochondrial function, O2-flux will be measured with high-resolution respirometry, at week 6 and week 12 of each intervention period|whole-body metabolic flexibility, insulin-stimulated change in respiratory exchange ratio will be determined with use of indirect calorimetry during the clamp, at week 12 of each intervention period|energy status of the heart, PCr/ATP-ratio will be determined with phosphorus magnetic resonance spectroscopy, at week 12 of each arm|cardiac function: ejection fraction, The cardiac function will be measured via ejection fraction (microL) with the use of cine-MRI, at week 12 of each arm|cardiac function: left atrial maximum volume, The cardiac function will be measured via diastolic cardiac function with the use of ultrasound (transthoracic echocardiography) with the following parameter: Left atrial maximum volume (ml), at week 12 of each arm|cardiac function: peak A-wave velocity (cm/sec), The cardiac function will be measured via diastolic cardiac function with the use of ultrasound (transthoracic echocardiography) with the following parameter: Peak A-wave velocity (cm/sec), at week 12 of each arm|cardiac function: pulsed wave TDI velocity (cm/sec) at lateral and septal basal regions, The cardiac function will be measured via diastolic cardiac function with the use of ultrasound (transthoracic echocardiography) with the following parameter: Pulsed wave TDI velocity (cm/sec) at lateral and septal basal regions, at week 12 of each arm|cardiac function: peak E-wave velocity, The cardiac function will be measured via diastolic cardiac function with the use of of ultrasound (transthoracic echocardiography) will be assessed with the following parameters: Peak E-wave velocity (cm/sec), at week 12 of each arm|cardiac function: tricuspid regurgitation systolic jet velocity, The cardiac function will be measured via diastolic cardiac function with the use of ultrasound (transthoracic echocardiography) with the following parameter: Tricuspid regurgitation systolic jet velocity (m/sec), at week 12 of each arm
|
